HSBC Maintains Buy on Biogen, Raises Price Target to $342
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Morten Herholdt maintains a Buy rating on Biogen (NASDAQ:BIIB) and raises the price target from $339 to $342.
May 03, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HSBC maintains a Buy rating on Biogen and raises the price target to $342.
The upgrade in the price target by HSBC reflects a positive outlook on Biogen's stock, suggesting potential upside. Such analyst actions often lead to short-term positive sentiment among investors, likely boosting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100